The estimated Net Worth of Ben R Taylor is at least $3.1 Thousand dollars as of 14 June 2019. Ben Taylor owns over 10,000 units of Tyme Technologies Inc stock worth over $3,100 and over the last 7 years Ben sold TYME stock worth over $0.
Ben has made over 1 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ben bought 10,000 units of TYME stock worth $10,100 on 14 June 2019.
The largest trade Ben's ever made was buying 10,000 units of Tyme Technologies Inc stock on 14 June 2019 worth over $10,100. On average, Ben trades about 2,000 units every 0 days since 2017. As of 14 June 2019 Ben still owns at least 10,000 units of Tyme Technologies Inc stock.
You can see the complete history of Ben Taylor stock trades at the bottom of the page.
Ben's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 17 STATE STREET - 7TH FLOOR, NEW YORK, NY, 10004.
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, and Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Tyme Technologies Inc executives and other stock owners filed with the SEC include: